Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.49 |
| ▸ | CTSK | P43235 | 9/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839068 | 0.90 | CTSS (0.49) | CTSSCTSKCTSBKDM4DCTSL | |
| SCHEMBL4839064 | 0.90 | CTSS (0.49) | CTSSCTSKCTSBKDM4DCTSL | |
| SCHEMBL321050 | 0.88 | CTSS (0.50) | CTSSCTSKCTSBKDM4DCTSL | |
| SCHEMBL4968810 | 0.88 | CTSS (0.50) | CTSSCTSKCTSBKDM4DCTSL | |
| SCHEMBL321049 | 0.88 | CTSS (0.50) | CTSSCTSKCTSBKDM4DCTSL | |
| SCHEMBL4035607 | 0.87 | CTSS (0.50) | CTSSCTSKCTSBCTSL | |
| SCHEMBL4968776 | 0.87 | CTSS (0.46) | CTSSCTSKCTSBKDM4DCTSL | |
| SCHEMBL7114124 | 0.81 | CTSS (0.56) | CTSSCTSKCTSBKDM4DCTSL | |
| SCHEMBL31724504 | 0.81 | CTSS (0.56) | CTSSCTSKCTSBKDM4DCTSL | |
| SCHEMBL6680680 | 0.81 | CTSK (0.43) | CTSSCTSKFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | CTSS 3002/4885CTSK 3111/4885KCNK3 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.